171 related articles for article (PubMed ID: 29947783)
1. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.
Garvey EP; Sharp AD; Warn PA; Yates CM; Schotzinger RJ
J Antimicrob Chemother; 2018 Oct; 73(10):2815-2822. PubMed ID: 29947783
[TBL] [Abstract][Full Text] [Related]
2. The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.
Wiederhold NP; Najvar LK; Garvey EP; Brand SR; Xu X; Ottinger EA; Alimardanov A; Cradock J; Behnke M; Hoekstra WJ; Schotzinger RJ; Jaramillo R; Olivo M; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987152
[TBL] [Abstract][Full Text] [Related]
3.
Wiederhold NP; Xu X; Wang A; Najvar LK; Garvey EP; Ottinger EA; Alimardanov A; Cradock J; Behnke M; Hoekstra WJ; Brand SR; Schotzinger RJ; Jaramillo R; Olivo M; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104280
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis.
Gazzoni AF; Capilla J; Mayayo E; Guarro J
Int J Antimicrob Agents; 2012 Mar; 39(3):223-7. PubMed ID: 22226648
[TBL] [Abstract][Full Text] [Related]
6.
Shaw KJ; Schell WA; Covel J; Duboc G; Giamberardino C; Kapoor M; Moloney M; Soltow QA; Tenor JL; Toffaletti DL; Trzoss M; Webb P; Perfect JR
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891599
[TBL] [Abstract][Full Text] [Related]
7. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.
de Carvalho Santana R; Schiave LA; Dos Santos Quaglio AS; de Gaitani CM; Martinez R
Mycopathologia; 2017 Oct; 182(9-10):855-861. PubMed ID: 28656554
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.
Giamberardino CD; Schell WA; Tenor JL; Toffaletti DL; Palmucci JR; Marius C; Boua JK; Soltow Q; Mansbach R; Moseley MA; Thompson JW; Dubois LG; Hope W; Perfect JR; Shaw KJ
mBio; 2022 Dec; 13(6):e0234722. PubMed ID: 36222509
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Jarvis JN; Lawrence DS; Meya DB; Kagimu E; Kasibante J; Mpoza E; Rutakingirwa MK; Ssebambulidde K; Tugume L; Rhein J; Boulware DR; Mwandumba HC; Moyo M; Mzinganjira H; Kanyama C; Hosseinipour MC; Chawinga C; Meintjes G; Schutz C; Comins K; Singh A; Muzoora C; Jjunju S; Nuwagira E; Mosepele M; Leeme T; Siamisang K; Ndhlovu CE; Hlupeni A; Mutata C; van Widenfelt E; Chen T; Wang D; Hope W; Boyer-Chammard T; Loyse A; Molloy SF; Youssouf N; Lortholary O; Lalloo DG; Jaffar S; Harrison TS;
N Engl J Med; 2022 Mar; 386(12):1109-1120. PubMed ID: 35320642
[TBL] [Abstract][Full Text] [Related]
11. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Brouwer AE; Rajanuwong A; Chierakul W; Griffin GE; Larsen RA; White NJ; Harrison TS
Lancet; 2004 May; 363(9423):1764-7. PubMed ID: 15172774
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
O'Connor L; Livermore J; Sharp AD; Goodwin J; Gregson L; Howard SJ; Felton TW; Schwartz JA; Neely MN; Harrison TS; Perfect JR; Hope WW
J Infect Dis; 2013 Jul; 208(2):351-61. PubMed ID: 23599314
[TBL] [Abstract][Full Text] [Related]
13. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.
Wiederhold NP; Shubitz LF; Najvar LK; Jaramillo R; Olivo M; Catano G; Trinh HT; Yates CM; Schotzinger RJ; Garvey EP; Patterson TF
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437615
[TBL] [Abstract][Full Text] [Related]
14. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner J; McEntee L; Johnson A; Livermore J; Whalley S; Schwartz J; Perfect JR; Harrison T; Hope W
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320715
[TBL] [Abstract][Full Text] [Related]
15. Influence of the progression of cryptococcal meningitis on brain penetration and efficacy of AmBisome in a murine model.
Takemoto K; Yamamoto Y; Ueda Y
Chemotherapy; 2006; 52(6):271-8. PubMed ID: 16988503
[TBL] [Abstract][Full Text] [Related]
16. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Sorrell TC; Patterson TF
Antimicrob Agents Chemother; 2013 Feb; 57(2):745-50. PubMed ID: 23165465
[TBL] [Abstract][Full Text] [Related]
17. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates
Wiederhold NP; Lockhart SR; Najvar LK; Berkow EL; Jaramillo R; Olivo M; Garvey EP; Yates CM; Schotzinger RJ; Catano G; Patterson TF
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30530603
[No Abstract] [Full Text] [Related]
18. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation.
Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
20. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
